Homeopathy is widely used in livestock, especially to replace or reduce the use of antibiotics in the treatment of infectious diseases, although its use is often seen as controversial. For organic agriculture, homeopathy is even promoted.
In the review, Dr Caroline Doehring and Professor Albert Sundrum from the University of Kassel, Germany, assessed peer-reviewed studies on the efficacy of homeopathy in cattle, pigs and poultry published between 1981 and 2014.
They analysed a total of 52 clinical trials, 34 with cattle, 12 with pigs and six with poultry. They were published in 48 publications.
Of these, 28 concluded that the homeopathic remedy administered was effective, 22 showed no efficacy and 2 were inconclusive.
Only 10 trials provided information on cure rates for the treatments. These varied to a high degree, while the remedy used did not seem to make a big difference.
Trials on pigs were frequently efficacious, while studies with cattle or poultry had a similar distribution of efficacious and non-efficacious treatment.
Double-blind randomised controlled trials reported efficacy of the homeopathic treatment almost as often as they reported lack of it.
Meanwhile, single-blind and non-blind randomised controlled trials, and observational trials were more likely to present evidence of efficacy, suggesting that positive outcomes may be due to bias.
Other study limitations, such as potential conflict of interests, low sample size, risk for selective reporting and bias, were found in the majority of trials.
While some clinical trials showed effectiveness, the authors of the review question the reliability of the evidence, because all studies had a range of limitations. For example, all clinical trials were conducted under very specific conditions and none were repeated under comparable conditions.
Therefore, the authors say the findings cannot be be used to recommend homeopathy: "The current evidence of studies providing evidence in favour of homeopathy lacks reproducibility and therefore cannot claim to have sufficient prognostic validity."
"Due to a lack of prognostic validity, replacing or reducing antibiotics with homeopathy currently cannot be recommended unless evidence of efficacy is reproduced by RCTs and proven in various farm practice conditions."
In its updated position statement, the association emphasises its support of current UK legislation and says it would like to see improved implementation of current laws, in particular when informed by an evidence-based welfare outcomes approach.
The BVA also recommends that any proposals to improve welfare during transport should embrace all forms of transport and include welfare issues before, during and after movement. This, it says, would help ensure that a well-defined set of animal welfare standards are met for the entirety of any journey.
The BVA recommends that animals are slaughtered as close to the point of production as possible and supports the exploration of further opportunities which would assist this. It recognises that transportation of live animals can be unavoidable in some situations – for example, journeys between the Scottish Islands and Highlands – but says that no animal should be exported to a destination with unknown welfare standards, to one using systems currently banned in the UK or to a country where it would be slaughtered without stunning.
BVA President Simon Doherty said: "Any kind of movement has the potential to impact on an animal’s health and welfare. Ideally, we’d like to see livestock slaughtered close to the point of production, as long as all legislative health and welfare standards can be maintained. However, we recognise the high standards of welfare in the UK and support better implementation of current legislation.
"We have taken care to reiterate that any improvements made to live animal transport should consider welfare issues before, during and after movement so that a more complete approach is taken on this issue.
"We recognise that journey length is not the only influencer of welfare conditions for animals, and transport needs to be looked at as a whole rather than focusing on single factors. The most important thing for Government to do is to consider the evidence base when it weighs up options for making improvements."
The British Veterinary Association (BVA) is calling on the Veterinary Medicines Directorate to classify all anthelmintics as POM-V, so that they can only be prescribed by a veterinary surgeon, rather than by vets and Suitably Qualified Person (SQPs) as at present.
The BVA has written to the VMD to request that changes are made to the Veterinary Medicines Regulations. The BVA is also supporting the efforts of the Federation of Veterinarians of Europe in lobbying the European Commission for tighter rules to be in place across all European Member States regarding the accessibility of anthelmintics.
The BVA says that at a time when expert opinion is increasingly alarmed at the growth in resistance to anthelmintics in grazing animals, it believes that it is important that all anthelmintics be classified as POM-V so that their use is conditional on appropriate veterinary advice for all species.
Many experts in parasitology have cited the distribution of anthelmintics by SQPs in the past as one of the main reasons for the dangerous levels of resistance to anthelmintics in grazing animals in the UK at present. SQPs do not have the level of expertise that a veterinary surgeon has in veterinary parasitology.
BVA is an active member of the Responsible Use of Medicines in Agriculture (RUMA) Alliance and in 2010 BVA launched a poster and detailed guidance for vets on how to prescribe and use anthelmintics responsibly. BVA's CPD Group is also working on a programme of CPD to reinforce the responsible use of these medicines.
Peter Jones, BVA President said: "We know that resistance to anthelmintics is a major problem that must be addressed vigorously if the livestock industry is to avoid a potentially disastrous situation of being unable to tackle parasites in grazing animals.
"Anthelmintics should only be prescribed by a veterinary surgeon who has the animals under his/her care and based on a sound clinical diagnosis.
"We strongly supported the VMD's recent decision to continue to classify the new anthelmintic product containing monepantel as POM-V, but the UK stands alone in Europe in classifying other anthelmintics as POM-VPS.
"The UK must be brought in line with the rest of Europe and we need Europe-wide legislation to better control access to anthelmintics in order to safeguard the efficacy of these products in the future."
BVA has added its voice to the Labelling Matters campaign for the introduction of mandatory method of production labelling of meat and dairy products. This would help consumers across the UK to answer the simple questions "How was this animal kept?" and "Did this animal die a humane death?", including stunning before slaughter.
A key element of the Labelling Matters campaign is that mandatory method of production labelling must be underpinned by robust welfare outcome safeguards, with on-farm welfare assessments ensuring that high welfare standards are being achieved.
Legislation for mandatory method of production labelling has been implemented already for shell eggs, which must legally be labelled either as “eggs from caged hens”, “barn eggs”, “free range” or “organic”. Labelling Matters wants to see this principle extended to meat and dairy products from other farmed animals.
The BVA highlights evidence which shows that consumers in the UK and across Europe want clear food labelling with information about animal welfare:
BVA President Sean Wensley said: "For vets it's a top priority that the animals we rear for food have a good life and a humane death. Research shows that vets are not alone in caring about where their food comes from. Mandatory method of production labelling makes sense on a number of fronts: consumers can be clearly and consistently informed about how the animals reared for their meat and dairy products were kept, with on-farm welfare assessments assuring high standards. Mandatory method of production labelling would give unambiguous information to the high numbers of consumers who care about animal welfare when buying meat and dairy products and help ensure market support for British farmers who pride themselves on achieving the highest welfare standards."
It seems that a series of one day conferences, organised by the Animal Health agency for vets and animal health inspectors involved in fighting bovine TB, haven't gone down as well as hoped.
According to a report in yesterday's Daily Telegraph, many in the audience were angered when they were asked to spend up to an hour playing a game involving bongo drums.
Incredibly, a spokesman for Animal Health apparently told the Daily Telegraph that: "It was meant to emphasise how people working together can build up a rhythm."
The Animal Medicines Training Regulatory Authority (AMTRA) is launching its new Continuous Professional Development (CPD) scheme today, designed to ensure that the Authority's registered Suitably Qualified Persons (SQPs) keep up to date with the latest animal medicines information.
In order to maintain their SQP status, every SQP will have to achieve a minimum number of CPD points during each AMTRA CPD period, running for two years from July to June. However, in the initial stages of the scheme, this first period will run for 33 months, from October 2008 to June 2011, allowing AMTRA to fine tune the system if required and give its SQPs time to get used to the new structure.
During these CPD periods, SQPs are required to obtain a minimum number of CPD points depending on their SQP type:
SQP Type: Modules; VPS medicines supplied; CPD PointsR-SQP: FAM+EQM+CAM; All VPS Medicines; 70 pointsG-SQP: FAM+EQM; VPS-farm animals and equines only; 50 pointsK-SQP: FAM+CAM; VPS-farm and companion animals only; 50 pointsE-SQP: EQM+CAM; VPS-equines and companion animals only; 50 pointsL-SQP: FAM; VPS-farm animals only; 30 pointsJ-SQP: EQM; VPS-equines only; 30 pointsC-SQP: CAM; VPS-companion animals only; 30 points
(FAM - Farm Animal Module, EQM - Equine Module, CAM - Companion Animal Module)
In essence, this means that 20 points are required per animal group, plus a further 10 points. Dr Roger Dawson, Secretary of AMTRA comments, "There is no maximum number of CPD points that SQPs can accumulate and we will be encouraging them to gain the benefit of as much CPD as they can."
Those SQPs who do not achieve the minimum number of CPD points by the end of the period will not be eligible to renew their status for the following year. However, such SQPs will have the option of sitting an examination before the end of that CPD period in order to maintain their SQP status and eligible be to renew for the next year.
SQPs will have a range of avenues through which to gain CPD points, ranging from four types of AMTRA-accredited CPD Events, to online study and personal study. With CPD Events and online studies, accreditation and points will be awarded by the AMTRA CPD Accreditation Panel. With personal study, AMTRA accepts a degree of self-certification of this form of CPD, however the points gained in this way are limited to a relatively small proportion of the minimum required in a CPD period.
Throughout a CPD period, all SQPs are required to attend at least ONE CPD Event. These events will comprise a range of modules that will be assessed for coverage, of relevant topics ranging from legislation, regulations and prevalence & effects of parasites and pathogens, to control of disease management, resistance, warnings and SARS.
Dr Dawson says, "The new CPD scheme has the necessary flexibility to allow SQPs to gain the required CPD points via a number of routes, from accredited CPD events and online study to personal study. Furthermore, the structure of the scheme ensures that their studies will be properly assessed to ensure they have gained the necessary knowledge to secure their CPD points."
The Veterinary Development Council (VDC) is conducting a survey to investigate the role of paraprofessionals and technicians in veterinary practice, and is asking vets in large animal, equine, and mixed practices to complete a short survey.
The VDC says that information from the survey will help inform discussions on the regulation of technicians.
The survey will take between 5 and 10 minutes to complete and can be found on the BVA website at www.bva.co.uk/vdc. The BVA has also emailed the survey directly to practices.
The survey has been devised by the VDC working group looking at the role of the veterinary-led team, chaired by BVA Past President Professor Bill Reilly. This is one of three working groups that will report to the VDC:
Professor Reilly said: "The relationship between veterinary surgeons and technicians is vital but it varies from practice to practice.
"The working group on the role of the veterinary-led team aims to take a snapshot of how services, such as artificial insemination and foot trimming, are currently delivered, and gauge how veterinary surgeons feel about other services being delivered by non-veterinarians in the future.
"I hope veterinary surgeons in large, mixed and equine practice will take 10 minutes to complete our survey to help us map the current use of technicians in veterinary practice and help shape our future discussions."
Boehringer Ingelheim Vetmedica has announced that it will be launching Bovela, a new viral diarrhoea (BVD) vaccine, to farmers during April 2015.
Allan Henderson from Boehringer said: "BVD remains the most common viral disease affecting cattle throughout Europe, despite vaccines being available for over 15 years. We asked farmers why this was the case and, without exception, they remarked that current vaccine protocols are unwieldy, requiring precise timings making them hard to follow.
"Bovela is a unique one-shot vaccine that can be used in cattle from three months of age and also whether pregnant or not. Other, currently available vaccines require a two-dose primary course with boosters annually or even every six months thereafter."
BVD is spread within herds and to new herds through the presence of persistently infected (PI) animals. PIs can look relatively healthy and show no outward signs of infection but, as they were exposed to the virus as a foetus, have become virus carriers. If they are born alive, they will shed virus consistently throughout their lives so perpetuating the cycle of infection.
Alan said: "The foetal control delivered by Bovela gives absolute confidence that cows will not produce PIs. This, alongside the drastically improved convenience will undoubtedly make Bovela the natural choice for many farmers, both on beef and dairy farms."
According to Boehringer, around 60% of cattle in the EU test positive for exposure to the BVD virus and, although BVD type 1 is currently the most common form, outbreaks of BVD type 2, were confirmed in 2013 and 2014 in Belgium, Germany and The Netherlands. BVD type 2 is generally a more serious disease, with high levels of mortality and while the virus has been identified in UK, it has not yet been identified as the cause of serious outbreaks of disease in cattle.
Alan said: "Bovela is the first and only vaccine in UK which has been proven to protect cattle from BVD type 1 and 2. It has been in development for 17 years and, gained a marketing authorisation following assessment of an unprecedented quantity of data generated in both beef and dairy herds.
"Work has looked at the efficacy of Bovela in preventing the production of PI calves and against type 1 and 2 BVD as well as confirming its efficacy in young calves as young as three months of age as their natural maternal protection wears off. Trials also confirmed vaccine safety generally and during various stages of pregnancy. We do not believe that any other BVD vaccine has been tested as rigorously."
Novartis Animal Health has launched a 0.5L pack of the anthelmintic Zolvix to make the product more readily available for quarantine dosing, and for the smaller sheep farmer.
Novartis says that because Zolvix is a broad spectrum anthelmintic that has the ability to kill all common sheep gastro-intestinal nematodes, including those resistant to existing treatments, it has a key role to play in quarantine treatment to keep parasite infection down to a minimum.
Simon Harris, Endoparasite Brand Manager at Novartis Animal Health, said: "As the first of the new generation of the Orange or 4-AD anthelmintic group, Zolvix has demonstrated effectiveness in killing worms, even those resistant to other products.
"Sheep farmers are being encouraged to use Zolvix as a quarantine treatment that can significantly reduce worm burdens on farm. I would stress that it is essential guidelines are followed in order to preserve Zolvix's ability to combat nematodes that have acquired resistance to other classes of wormers.
"This new pack size is aimed at farmers who are introducing new stock to their flocks, but will also be convenient for the smaller sheep farmer and smallholders who don't require such a large quantity of product."
Novartis says that because Zolvix is a short-acting anthelmintic, it does not encourage resistance to develop through a long duration of action. It has a high margin of safety so can be used to treat sheep and lambs including pregnant or lactating ewes and breeding rams. Its short meat withhold period of just seven days allows flexibility when marketing lambs.
The 2009 edition of the NOAH Compendium Data Sheets for Animal Medicines is now being dispatched, free of charge, to each practice premises.
Meanwhile, the online version of the compendium (www.noahcompendium.co.uk), launched 3 years ago to provide a free and convenient source of information about animal medicines for both prescribers and consumers, has just had its 9 millionth page view. The site gets about 3000 visits a day.
Whilst it is possible to order additional print copies of the compendium, NOAH points out that the online version has the beauty of being updated every week with new products, indications and other data. Plus the site is searchable by active ingredient, species, therapeutic indication or text search.
NOAH chief executive Phil Sketchley said: "We try to make the online Compendium as useful and as quick and easy to use as it can be, and while we have received overwhelmingly positive feedback we are always interested to hear how you think it could work better for you, so we can keep this in mind for any future improvements".
Vetoquinol has introduced a new smaller pack size for Reprocine, to help prevent wastage. The new 6 x 10ml pack is now available from wholesalers.
Reprocine is licensed in the cow for uterine atony during the puerperal (post-parturient) period, placental retention as a consequence of uterine atony and initiation of milk ejection in a stress-induced agalactia or in conditions requiring udder emptying. In the sow, Reprocine is licensed for uterine atony during the puerperal period also, supportive therapy of mastitis-metritis-agalactia (MMA) syndrome, initiation of milk ejection and for shortening of parturition period. Reprocine is an intraveneous or intramuscular injection and has the added advantage of no milk or meat withdrawal.
Susan Mitchell, Vetoquinol's Large Animal Product Manager said: "The new pack size reduces wastage which provides an instant cost-effective advantage.
"Reprocine is rapidly distributed and slowly eliminated. Efficient parturition and milk ejection is essential for newborn welfare and ultimately provides an economic benefit. Reprocine can be utilised in many reproductive associated conditions."
Reprocine is also available in 50ml bottles.
5638 events were reported spontaneously, mainly by the marketing authorisation holder (61%), with the remainder largely reported by veterinary surgeons.
Of these, 5512 were reports of adverse reactions in animals: 829 concerning suspected lack of efficacy, 4638 concerning safety. The majority of reports concerned dogs (2927), cats (1426) and cattle (386).
In dogs, medicines for the control of epilepsy were most often suspected of not having performed as expected (80 reports) whilst vaccines were most commonly reported as having failed to work (71). However, the VMD points out that in many cases, vaccination failure was attributable to other causes (such as incomplete vaccination schedule).
In cats, flea spot-on products were most likely to be reported as not having worked (21). However, there are many reasons why owners may continue to see live fleas on their animal which are unrelated to product efficacy (such as reinfestation from the environment).
Notably, the majority of efficacy reports in horses (12/19) related to euthanasia products, which the report says should serve as a reminder that alternative means of euthanasia should always be available in case the chosen method does not proceed as planned.
Of the safety reports, 59.6% involved dogs, 31% cats, 4.9% horses and 3.9% rabbits. The majority concerned vaccines (1360 reports, most commonly general signs or symptoms, such as lethargy or pyrexia), parasiticides (472 reports, most commonly lethargy, emesis, inflammation/pruritus, depending on method of administration) and inflammation control (412 cases, most commonly emesis, renal insufficiency and diarrhoea, depending on the drug type).
There were 124 reports of adverse events in humans. Of those involving veterinary professionals (about a quarter):
The VMD says that reports of needle stick injuries involving vaccines with a mineral oil adjuvant are of particular concern, because they often fail to show that the injured party has received prompt and correct treatment, either because they are themselves unaware of the necessity for swift intervention, or because they do not take the product package information leaflet with them when seeking medical treatment.
Similarly, the VMD says that incidents involving injectable tilmicosin seem to be often dismissed as just a scratch, and that if you use these products, you should make sure you are fully aware of the warnings contained in the product leaflets.
To read the full report, visit: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/608968/PhV_Annual_Review_2015_v7.pdf
However, the report also indicates an opportunity for further uptake of teat sealant use as part of selective dry cow therapy.
The report is based on data collected from 940 dairy farmers and 156 vet practices.
Report author Christina Ford said: “The overall message from the report is exceedingly positive.
"79% of herds met the Ruma 2020 target by March 2021, and the decline in use of critically important antimicrobials was outstanding, a drop from 1.1 mg/kg PCU in 2018 to 0.02 mg/kg PCU in 2021.”
There was a large variation between individual herd results, which ranged from 0.28 to 87.51mg/kg PCU in 2021.
Christina said: “We found that it’s not always the same herds in the highest 25% antimicrobial usage year-on-year, nor is it necessarily the same farms consistently using the lowest quantities.
“There’s also no correlation at all when looking at different herd characteristics such as yield, herd size, breed.
"This demonstrates that it’s possible to make strides in reducing antimicrobials use in any farming system."
Senior clinical director at Kingshay, Tim Potter MRCVS says the report shows an opportunity for increased uptake of teat sealants to protect cows from infection without antibiotics.
“The teat sealant usage in 2021 was at 0.39 courses/cow, which was below the Ruma target of 0.7 courses per cow.
“Last year, 37% of herds were not using teat sealants at all, so there’s definitely room for improvement.
"Vets, farmers and wider industry need to work together to address the challenges around teat sealant use.
“Appropriate training around use of teat sealants is essential, as improper use and poor hygiene protocols can result in bacteria being trapped inside the udder, having the opposite effect on cow health and productivity.”
Tim says that vets are seeing increased demand from farmers for training in this area.
“As a result, VetPartners has invested in the training of our vets, and specific training aids to enable us to do this effectively, to ensure we’re able to support our farmers as best we can.”
The first annual Dairy Antimicrobial Focus Report can be downloaded from: https://www.kingshay.com/dairy-costings/dairy-antimicrobial-focus-report/
The study, which examined cattle farmers’ and veterinary surgeons' opinions of pain-induced distress associated with disbudding, analgesia and attitudes and the use of non-steroidal anti-inflammatory drugs (NSAIDs), suggests that in particular, vets need to refine their understanding of farmers’ priorities, and how they guide clients on methods to improve calf welfare.
There have been a number of studies into the pain-induced distress resulting from the disbudding procedure. All methods of disbudding (apart from chemical cauterisation) in the UK require the use of a corneal nerve local anaesthetic blockade but there are currently no legislative requirements for the use of NSAIDs for disbudding – it is at the discretion of the farmer or veterinary surgeon carrying out the procedure. NSAIDs are routinely used in companion animals and equine practice, but less so in farm animals.
This new study, conducted by researchers at the Royal Veterinary College (RVC) in Hertfordshire and Aran Vet Clinic in Gwynedd, looked at the attitudes of farmers and vets on pain perception and pain management methods for disbudding. A total of 118 vets and 140 farmers contributed to the study. Of the respondents:
The study concluded that veterinary surgeons underestimate the influences of welfare and analgesic duration and effectiveness on farmers' decisions, and overrated cost impact. This perception could have a negative effect on veterinary recommendation.
The authors of the study therefore advise that steps should be taken to address the current inadequacies in the communications between vets and clients in conveying the practicalities and potential benefits of using NSAIDs.
Dr Troy Gibson, PhD, PGDipSci, BSc, Lecturer in Animal Welfare Science at the Royal Veterinary College said: "Despite the large amount of evidence of the benefits of NSAIDs for disbudding, it is disappointing that their use is still not widespread. This may partly be due to the only recent licencing of one NSAID for cattle. However, from our work it is clear that one of the key barriers to wider uptake is the breakdown in communication between veterinarians and their clients in conveying the cost, practicalities and potential benefits of NSAID use for disbudding. The wider use of NSAIDs in combination with local anaesthetics during disbudding would significantly improve calf welfare."
Reference
PBD Biotech says the Actiphage test offers the potential to revolutionise control of bovine TB by allowing detection of the disease within hours from a blood or milk sample.
Last November, the Welsh Government announced a new policy that allowed the use of non-validated tests such as Actiphage in herds affected by a TB breakdown. It followed a similar protocol to one authorised by the UK Government last year for cattle herds in England after the test was used as part of a successful private eradication plan on a Devon dairy farm.
Mossman Farming, in Ceredigion, is located in an area of chronic breakdown. It is a spring-calving milking herd with a total stock of 529, to date 312 dairy cows have been slaughtered. Farmer Chris Mossman agreed to trial Actiphage after hearing about the Gatcombe pilot.
Chris said: "TB is a massive problem in Ceredigion, so when I heard about Actiphage’s use at Gatacombe, helping to clear that dairy herd for the first time in six years, I wanted to try and replicate those findings here. Me – and many other farmers – are losing large numbers of animals. I’m trying to do all I can to get rid of this disease from my herd."
In Spring 2019, The Office of the Chief Veterinary Officer for Wales granted permission for Robert Price-Jones MRCVS to use Actiphage to screen high-risk cattle for M. bovis.
Robert, who has been leading the trial, said: "Actiphage is able to identify the presence of relatively low numbers of M. bovis in the blood stream of infected cattle. It is not dependent upon an immune system response to the pathogen - in contrast to current validated tests - and so has greater sensitivity than such as the official Tuberculin SICCT skin test.
"The benefit of using Actiphage is that it offers the potential for eradicating the disease from the farm; as early identification of animals at risk of bovine TB enables heightened disease management and control."
Under the terms of the Welsh Government’s protocol, cattle not condemned for slaughter can be tested with Actiphage. Those that give a positive result are identified with a ‘management’ marker, monitored and milked separately.
To prevent further contamination of the environment and to minimise risk to uninfected cattle, animals found to be ‘shedders’ are removed from the farm.
Although a decision to remove cattle based on a non-validated test will be at the farmers’ own expense, the APHA (Animal and Plant Health Agency) has confirmed that during the trial, where a positive result is confirmed with statutory tests, the animals will be removed with compensation as normal.
So far, 100 animals from Mossman Farming have been tested with Actiphage and Robert Price-Jones is preparing a paper to publish the findings in early 2020.
PBD Biotech is now seeking more farms to trial Actiphage in order to gain the World Organisation for Animal Health (OIE) validation. The company is offering reduced cost testing to support trials where the findings are made available to support validation of the test.
Dairy nutrition consultant Hefin Richards of Profeed Nutrition Consultancy is warning vets to be on the lookout for an upsurge in over-conditioned cows as winter progresses through spring.
He says his prediction is based on a number of factors that have come together over the last year to greatly increased the risk of cows being over-conditioned at calving, not only potentially affecting productivity but predisposing to a number of clinical conditions.
A high body condition score at calving significantly increases the risk of subclinical ketosis in early lactation, depressing the immune response and increasing the risk of conditions such as retained foetal membranes, metritis and left displaced abomasum.1,2 Conversely, these obese cows go on to suffer excessive body condition loss due to decreased voluntary feed intake and poor energy metabolism.
The ketosis risk has been increased in part because national milk yields were low last summer and autumn as a result of poor weather conditions, low milk prices, high feed costs and the spread of Schmallenberg virus (SBV).3
Hefin said: "SBV and bad summer weather with associated poor forage quality may have delayed rebreeding, leading to more extended lactations and longer dry periods. These two factors can lead to excessively fat cows at calving."
Through the winter many herds were running average milk yields some way below usual winter levels and currently mid and late lactation cows are substantially under target yields.4 This lower yield means that feed intake is very likely to be in excess of actual energy demands, with subsequent fat deposition.
Increasing awareness of this potential issue gives vets the opportunity to reinforce the need to monitor body condition, adjust feeding, review milk yields and consider drying cows off early, using controlled energy feeding.
Hefin suggests that vets ensure that their clients' dry cow nutrition and management is geared towards maximising feed intake in early lactation to help prevent animals falling into a state of negative energy balance. Ketosis is often missed on farm because the signs are not apparent. Consider routinely monitoring herds for ketosis using either blood monitoring or Elanco's Keto-Test cow-side milk test to identify both at-risk cows and herds. Forming a team involving vets, nutritionists and herd managers and harnessing the different skill sets and knowledge allows strategies to be developed that can improve herd performance.
References
Launched in 2023 to address the growing need for skilled farm vets, the VetPartners Farm Academy was created to provide more opportunities for future vets to gain hands-on experience.
VetPartners Farm Director Ian Cure said: “By opening up on-farm and simulated farm experiences to students, the academy aims to bridge the gap between veterinary education and practical farm work – ensuring a strong pipeline of talent into the industry.
“Designed by farm vets, for vets of the future, our three-day academy complements university education by providing veterinary students with a structured on-farm experience that builds confidence and prepares them for a career in farm practice.
“By welcoming students into the Farm Academy, we’re helping them develop the practical skills, confidence and knowledge needed to thrive in farm animal practice from day one.
"The academy also offers those students who haven’t had previous farm exposure the chance to try farm vetting for the first time.
“With the agricultural sector facing increasing pressures, from sustainability targets to animal health challenges, ensuring the next generation of farm vets is well-prepared is more important than ever.”
This year’s academy will take place at a VetPartners practice in Cornwall, from 14th to 16th June.
Students will receive training from experienced farm vets, and gain valuable skills in herd health, disease management, and sustainable livestock production.
The Farm Academy programme in 2025 will offer students:
To apply, send a CV and covering letter to farmsupport@vetpartners.co.uk
Applications close 25th April.
Pfizer Animal Genetics is expanding its presence in the UK with the appointment of a dedicated team.
The company says it will use state-of-the-art genetic technology to improve the health, welfare and productivity of animals, and that the move comes at an exciting time for genetic research, as complete sequencing of the bovine genome has resulted in explosive growth of the possibilities.
As well as being able to provide tests addressing parentage (SireTRACE) and traceability (SureTRAK), Pfizer Animal Genetics can also help farmers identify the genetic potential that each animal has to produce tender, well marbled meat and to perform at optimal feed conversion efficiency (GeneSTAR) - vital management information that can improve profitability and enable effective decision making in long term breeding plans.
The company promises there is more to come, with exponential growth in the identification of genetic markers, which will allow the imminent introduction of new tests set to provide much more detailed predictive information about individual animals - all available virtually from birth onwards.
Richard Chew (above right) is Customer Service Manager and the first port of call for anyone with questions about pricing & submission forms, samples and reports. Richard grew up in rural Lancashire and went on to study at the University of Bristol. Since graduation his career has taken him through a variety of scientific and customer facing roles. He has worked for Pfizer Animal Health for six years in the clinical development of vaccines and pharmaceuticals for livestock and is looking forward to the new challenges of the genetics business. Richard is based in Pfizer's Surrey office and can be reached on 08345 3037398 or PfizerAnimalGenetics-EU@pfizer.com.
Mike Marron and Peter Quigley are Dairy Sales Manager and Beef and Sheep Sales Manager respectively and will be the contact points for breed associations, organisations and individuals who want to discuss how genetic assessment and identification can help assure the quality of a breed or herd. Mike has an honours degree in biological and biochemical science and a decade of experience in the animal health industry, with special interests in fertility and calf management. Peter also comes from the animal health industry and is looking forward to continuing the company's work with the Aberdeen Angus Society as well as developing programmes for other beef breed societies.
Mike or Peter will be in attendance at various agricultural shows across the UK including Agrilive, the South West Dairy Show, Surecalf, Agriscot, Thainstone Christmas Classic, the Welsh Winter Fair, The Great Yorkshire Show and the Northern Ireland Winter Fair, where they will be explaining how genetic testing can make a contribution towards improving the brand value of a breed and shortening the time frame to allow better management decisions to be made.
Dr Gary Evans is Technical Services Manager and will be providing detailed advice on how to improve pedigree herd books, the interpretation of results of genetic testing and detection of certain genetic diseases. Gary is a geneticist with fourteen years experience in the application of genomics to livestock and joins Pfizer Animal Genetics from PIC/Genus.
A new injector gun for administering doramectin-based worm and scab medication to sheep has been introduced by Pfizer Animal Health. According to senior livestock vet Carolyn Hogan, the intra-muscular injection route for this medication combined with the injector’s prime-and-push design allows a single arm movement to penetrate the skin and dispense the treatment.
Lord Rooker, Minister for Sustainable Food, Farming and Animal Health has announced seven new members to the Veterinary Residues Committee (VRC).
The VRC’s role is to advise the Chief Executives of the Veterinary Medicines Directorate (VMD) and the Food Standards Agency (FSA) on the formulation of the residues surveillance programmes and on the significance of the results in terms of consumer safety.
The seven new members who have been appointed to serve on the VRC from January 2009 until December 2012 are:
The appointments were undertaken in accordance with the Code of Practice issued by the Office of the Commissioner for Public Appointments.
The interactive map, which has been launched as part of Ceva’s ‘For Flock’s Sake – Vaccinate!’ awareness campaign, uses data from the company’s on-farm testing for Chlamydophila abortus, the bacterium that causes EAE.
Ceva says the map shows that the disease is present across the UK, although cases may well be much higher than shown, as the map is only based on farms that the company has tested positive for the bacterium.
Positive EAE cases on farms are recorded by county on the map, so farmers can check for EAE in their area.
The map, available at www.eaemap.co.uk, will be updated regularly as new farms test positive for EAE.
Stephenie Clarke, product manager at Ceva Animal Health, said: "Our new EAE interactive map will be updated on an ongoing basis and will be a useful tool to ensure that farmers are up-to-date with EAE cases throughout the UK."
For more information, visit www.eaemap.co.uk, contact your local Ceva Animal Health account manager, call Ceva on 01494 781510 or email: cevauk@ceva.com.
BPEX is looking for a few more veterinary surgeons to test its Real Welfare smartphone app, which is used to collect data regarding welfare outcomes in pigs.
BPEX says it will pay vets for their time carrying out the testing but it needs regular submissions of data to give both Android and iOS a good workout.
Project Manager Katja Stoddart said: "It has been a long and sometimes difficult journey but the app is now performing well on both platforms and we are receiving positive feedback from those using it.
"That does not mean there are no problems but those that do crop up are now minor and can easily be dealt with.
"We still need a handful more vets willing to do the testing but we must stress we need regular data submission to make it worthwhile."
Ultimately the app will replace the bureau service which has only been extended until the end of this year so vets will need to change over before the bureau closes.
Katja said the portal will continue so vets can do the assessments in paper form then transfer via a computer but it will be much quicker and easier in the long run to input in real time using the app.
She added: "This will also mean the data is available immediately for the vet to discuss with the producer."
Veterinary practices are being encouraged to enter the annual Veterinary Marketing Association's (VMA) awards, which now include a practice-only category.
The annual VMA awards are intended to recognise excellence in all aspects of veterinary and animal health marketing. The Practice Marketing Award, sponsored by Pfizer, is awarded to the companion or production animal practice that demonstrates the most initiative and innovation in the marketing of its products and/or services to end users. This can involve the use of any form of activity, including advertising, websites, direct mail and media relations.
Last year's winner of this award was Kessock Equine Vets from Aberdeen, who travelled down to London to receive their award at a presentation lunch. The 2009 awards presentation ceremony takes place on Friday, 19th March at the Old Brewery in Chiswell Street, London. The meeting also presents a very good opportunity for vets to meet representatives from all the major animal health companies.
Tickets for the event cost £115+VAT for VMA/VMPA members (£150+VAT for non-members). The price includes a three-course meal (prepared by a two-star Michelin chef) with wine, a champagne reception and entertainment by a top comedian.
Further information on the awards is available on the Veterinary Marketing Association's website - http://www.vma.org.uk/. Closing date for entries is 5th February 2010.
BCF Technology has launched a competition in which the person who submits the best photograph with the theme of: All in a day's work - animal imaging, will win an iPad 2.
To enter the competition, you need to post your photographs, (and tell BCF a little about the story behind the images) at www.facebook.com/bcftechnology or email them to: info@bcftechnology.com
Jason Rogers, Marketing Manager at BCF said: "We wanted to create a fun way to show just how interesting and different each days work is when imaging animals. We have made the competition open to all that work with animal imaging including our staff, dealers and vets, vet nurses, animal contractors, etc from all over the world.
"It is great to see the BCF office in the States and our international dealers also promoting the competition in their own countries, making the competition truly international. Response to the competition has been fantastic - see our facebook page to some entries for yourself."
The closing date for the competition is 30th September 2011.
For more information, visit: www.bcftechnology.com